Amyloidβ-based therapy for Alzheimer’s disease:challenges,successes and future

作     者：Yun Zhang Huaqiu Chen Ran Li Keenan Sterling Weihong Song Yun Zhang;Huaqiu Chen;Ran Li;Keenan Sterling;Weihong Song

作者机构：National Clinical Research Center for Geriatric DisordersXuanwu HospitalCapital Medical UniversityBeijingChina The Second Affiliated Hospital and Yuying Children’s HospitalInstitute of AgingKey Laboratory of Alzheimer’s Disease of Zhejiang ProvinceWenzhou Medical UniversityWenzhouZhejiangChina Townsend Family LaboratoriesDepartment of PsychiatryThe University of British ColumbiaVancouverBC V6T 1Z3Canada Oujiang Laboratory(Zhejiang Lab for Regenerative MedicineVision and Brain Health)WenzhouZhejiangChina 

出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)

年 卷 期：2023年第8卷第7期

页      面：3374-3399页

核心收录：

学科分类：1002[医学-临床医学] 100203[医学-老年医学] 10[医学] 

基　　金：We thank Brian J.Song’s editing and comments.This work was supported by the National Natural Science Foundation of China(82201576) Beijing Hospitals Authority Youth Programme(QML20210804) Beijng Medical Research 2021-8(YZ) the National Natural Science Foundation of China(82150710557,82230043 and 82293642)to WS.WS was the Canada Research Chair in Alzhaimer’s Disease 

主　　题：Alzheimer Aβ clinical 

摘      要：Amyloidβprotein(Aβ)is the main component of neuritic plaques in Alzheimer’s disease(AD),and its accumulation has been considered as the molecular driver of Alzheimer’s pathogenesis and progression.Aβhas been the prime target for the development of AD ***,the repeated failures of Aβ-targeted clinical trials have cast considerable doubt on the amyloid cascade hypothesis and whether the development of Alzheimer’s drug has followed the correct course.